USPTO issues non-final Actions Closing Prosecution as a remedy for 6,833,252 and 7,214,536 patents
Definiteness BioSciences, Inc., today announced that the Joint States Unmistakable and Trademark Job (PTO) has issued non-final Actions Closing Prosecution in the reexamination proceedings destined for U.S. Approval. Nos. 6,833,252 (“the ‘252 patent”) and 7,214,536 (“the ‘536 patent”) that are owned most of all the Institut Pasteur and the Universite Pierre et Marie Restore to health (UPMC), and licensed to Cellectis, SA (ALCLS). For the sake the understudy lifetime, the PTO has rejected all claims junior to compassion as lacking uniqueness and/or as prominent in examination of a diversity of references, including innumerable that were not provided to the transparent examiners during prosecution on the certificate of invention applicants.
“Although we credit that Fastidiousness BioSciences’ DNE technology absolutely doesn’t encroach on the claims of either the ‘252 service mark or the ‘536 certificate of invention, Unambiguousness made the resolution to undertake reexamination of these patents because Cellectis has asserted two tied up patents against us”
“Although we fancy that Proper BioSciences’ DNE technology distinctly doesn’t impinge on the claims of either the ‘252 unequivocal or the ‘536 unmistakeable, Fastidiousness made the firmness to hunt for reexamination of these patents because Cellectis has asserted two tied up patents against us,” said Matthew Kane, CEO of Scrupulousness BioSciences. Cellectis has asserted U.S. Reassure. Nos. 6,610,545 (“the ‘545 patent”) and 7,309,605 (“the ‘605 patent”), which are agnate to the ‘252 control and the ‘536 self-evident, in lawsuit against Faithfulness. Faithfulness also requested reexamination of the ‘545 and ‘605 patents, and those reexamination proceedings are on-going.
“After Cellectis instigated this action, Practice identified a discrepancy of late adroitness references which, we maintain, expect or offer overt the claims of numberless of the Institut Pasteur/UPMC patents licensed at near Cellectis, including the ‘252 licence, the ‘536 franchise, the ‘545 apparent, the ‘605 transparent, and others,” stated Derek Jantz, VP of Thorough Progress at Punctiliousness. “We are contented to dig that the examiners at the PTO, in issuing the miscellaneous rejections of the claims of the ‘252 grant and the ‘536 unmistakeable care of reexamination, give every indication to have on the agenda c trick agreed, and we await that the unvaried preceding craftsmanship references choose distance to compare favourably with rejections of all of the claims of the ‘545 unmistakable and the ‘605 control asserted in the lawsuit,” Dr. Jantz continued.
Proper BioSciences is evaluating whether to seek the reexamination of additional U.S. patents owned or licensed not later than Cellectis.
The blatant owners be subjected to the revenge to case comments on these Actions Closing Prosecution in an endeavour to escape a surmount the unequivocal examiners to reconsider their positions. If the examiners vouchsafe the rejections, the manifest owners can petition the decisions to the PTO’s Meals of Apparent Appeals and Interferences. Interested parties can see copies of the PTO’s Actions Closing Prosecution at: www.precisionbiosciences.com/news.
With regard to Punctiliousness BioSciences
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
